Shots: The Atherosclerosis Risk in Communities (ARIC) study results involves assessing of high-sensitive troponin-I blood test in 8,121 candidates with no known cardiovascular disease aged 54-73yrs. for 15yrs. The ARIC study results identified the risk of cardiac events by measuring the elevated troponin-I levels, 85% had detectable troponin, adults with high troponin-I level are twice, […]Read More
Shots: AstraZeneca & BenevolentAI enter into an agreement to discover & develop therapies for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF) utilizing artificial intelligence (AI) and machine learning AstraZeneca will combine its genomics, chemistry and clinical data with Benevolent AI’s target identification platform and biomedical knowledge graph (network of genes, proteins, diseases and […]Read More
Shots: Janssen enters into an agreement to utilize Iktos’ AI (in silico drug design) technology for the enhancement of speed & efficacy of its small molecules discovery platform and will develop new therapies utilizing Iktos’ know-how in deep generative models applied to chemistry with its own AI expertise Additionally, Iktos has also collaborated with other […]Read More
Shots: The submission is based on P-III ATLAS (Antiretroviral Therapy as Long-Acting Suppression) and FLAIR (First Long-Acting Injectable Regimen) studies results assessing Cabotegravir + Edurant (rilpivirine) (injected monthly) vs SOC (three-drug regimen) in 1,100+ patients infected with HIV + viral suppression across 16 countries for 48wks. The P-III ATLAS & FLAIR studies resulted in maintaining […]Read More
Shots: EirGenix to receive upfront, milestones with profit sharing on sales and will be responsible for the development & manufacturing of proposed biosimilar trastuzumab. Sandoz to get WW rights to commercialize the proposed biosimilar trastuzumab (Ex- China & Taiwan) The agreement is the third biosimilar collaboration for Sandoz in 18 months, which will further focus […]Read More
Shots: The positive opinion is based on largest pre-registration clinical programme assessing Esperoct (FD, IV, q4days) in 270 patients previously treated with severe hemophilia A and more than 5 years of clinical exposure The study resulted in effective routine prophylaxis in people with severe hemophilia A, efficacious in treatment and control of bleeding episodes […]Read More
Shots: The approval is based on a P-III study results assessing Eticovo vs the reference product (Enbrel) in 596 patients with rheumatoid arthritis across 70 sites in 10 countries The study resulted in ACR20 (80.8% vs 81.5%) for 52 wks. confirming results of 24 wks. study in (78.1% vs 80.3%) Eticovo (etanercept-ykro) is a biosimilar […]Read More
Shots: The AcQMap contact mapping is a software offering physicians with multiple options to inform individualized therapy, to reconstruct atrial anatomy utilizing ultrasound and mapping electrical patterns with non-contact, charge density technology creating 3D real-time images Acutus’ Robust Second-Generation Platform has received FDA’ approval used for patients with electrophysiology procedures to reconstruct the chamber with […]Read More
Shots: The authorization is based on inTandem study consisting of three P-III trials assessing sotagliflozin (200/400 mg) vs insulin as monothx in 3000 adults with inadequately controlled T1D The study resulted reduction in average blood sugar (HbA1c), body weight, systolic blood pressure, improvement of time in target blood sugar range, patient-reported outcomes within 24 weeks […]Read More
Shots: The positive opinion is based on SOLO-1 P-III study results assessing Lynparza (300mg, bid) as a monothx vs PBO in 391 patients in ratio (2:1) with BRCAm advanced ovarian cancer following 1L Pt-based CT The study resulted in 70% reduction in the risk of disease progression or death and demonstrated PFS as (60.4% vs […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
